Jones Day (New York)

Sarah A. Geers

Jones Day (New York)

Sarah Geers represents pharmaceutical clients in intellectual property litigation in a variety of venues, including in district court, arbitration, and at the Patent Trial and Appeal Board (PTAB). Her practice spans Hatch-Waxman and other patent infringement actions, inter partes review proceedings, trade secret, and misappropriation actions. Her litigation experience spans discovery, trial, and appeal. arah is currently an adjunct professor at Seton Hall University School of Law, where she teaches a course on patent litigation. Sarah was named a Law360 Life Sciences Rising Star in 2020, which is awarded to lawyers under 40 whose legal accomplishments belie their age. Before becoming a lawyer, Sarah worked as a research chemist at Merck & Co., where she was responsible for solid dosage form development and associated preformulation research.

Auteurs associés

Jones Day (Sydney)
Jones Day (Mexico)
Jones Day (Brussels)
Jones Day (New York)
Jones Day (Brussels)


193 Bulletin

Sarah A. Geers, Jonathan Berman, Larissa Bergin, Rosanna McCalips, Ryan C. Thomas The US Court of Appeals for the Fifth Circuit rules that showing the reverse payment settlement eliminated the possibility of an earlier generic entry is enough to infer anticompetitive effect (Endo / Impax)


In Short The Background : In the Supreme Court’s landmark 2013 decision in FTC v. Actavis, the Court determined that large payments by branded drugmakers to potential generic entrants to settle patent disputes could be anticompetitive. It instructed district courts to apply the "rule of reason" (...)

Envoyer un message